A Phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies.

药代动力学 医学 毒性 中性粒细胞减少症 限制 喜树碱 药理学 最大耐受剂量 入射(几何) 化疗 内科学 胃肠病学 化学 工程类 有机化学 物理 光学 机械工程
作者
Mitchell Garrison,Lisa A. Hammond,Charles E. Geyer,Garry Schwartz,Anthony W. Tolcher,Leslie Smetzer,José A. Figueroa,Murray P. Ducharme,John Coyle,Chris H. Takimoto,Robert L. De Jager,Eric K. Rowinsky
出处
期刊:PubMed 卷期号:9 (7): 2527-37 被引量:7
链接
标识
摘要

The purpose of this study was to assess the feasibility of administering exatecan, a water-soluble, potent camptothecin analogue, as a protracted 21-day continuous i.v. infusion (CIVI). The study also sought to determine the maximum tolerated dose (MTD) of exatecan on a 21-day CIVI schedule, characterize its pharmacokinetic behavior, and seek preliminary evidence of anticancer activity.Exatecan dose-schedule development was performed in two stages using the modified Continual Reassessment Method and single patient cohorts. First, patients with advanced solid malignancies were treated with exatecan (0.15 mg/m(2)/day) as a CIVI for 5 days, and the duration of the CIVI was incrementally increased from 5 to 21 days. In the second stage of the study, the dose was incrementally increased to derive a tolerable dose of exatecan administered as 21-day CIVI. The MTD was defined for both minimally pretreated (MP) and heavily pretreated (HP) patients as the highest dose level at which the incidence of dose-limiting toxicity does not exceed 20%.Thirty-one patients were treated with 100 courses of exatecan at 6 dose-schedule levels. The incidence of the principal dose-limiting toxicities, neutropenia and thrombocytopenia, was unacceptably high at exatecan doses exceeding 0.15 mg/m(2)/day as a 21-day CIVI, which was determined to be the MTD for both MP and HP patients. The pharmacokinetics of exatecan were dose-proportional, and mean [coefficient of variation (percentage) steady-state concentration (plasma concentration at steady-state)] values ranged from 6.88 (80.6) to 19.41 (74.2) ng/ml at exatecan dose levels ranging from 0.15 to 0.30 mg/m(2)/day, which are similar to IC(50) values against human tumor cell lines treated for shorter periods. Mean pharamacokinetic parameters for total exatecan derived from a compartmental model included clearance and volume of distribution values of 1.39 (86.9) liters/h/m(2) and 39.66 (197.4) liters, respectively. Two HP patients with non-small cell lung and unknown primary carcinomas had partial responses, and objective evidence of anticancer activity and clinical benefit were noted in several other individuals.The administration of exatecan as a 21-day CIVI at doses as high as 0.15 mg/m(2)/day is safe and feasible for both MP and HP patients. The characteristics of the myelosuppressive effects of exatecan on this schedule, the paucity of severe nonhematological toxicities, and documented anticancer activity in several drug-refractory malignancies warrant further evaluation of the merits of administering exatecan by either a CIVI or alternate drug delivery systems to achieve protracted systemic exposure.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
B2B发布了新的文献求助30
1秒前
脑洞疼应助ZZZ采纳,获得10
2秒前
小菡菡完成签到,获得积分10
4秒前
5秒前
成就的白羊完成签到,获得积分10
5秒前
CodeCraft应助科研通管家采纳,获得10
7秒前
脑洞疼应助科研通管家采纳,获得10
7秒前
7秒前
地表飞猪应助科研通管家采纳,获得10
7秒前
科研通AI2S应助科研通管家采纳,获得10
7秒前
传奇3应助科研通管家采纳,获得10
7秒前
情怀应助科研通管家采纳,获得10
7秒前
英俊的铭应助科研通管家采纳,获得10
7秒前
YamDaamCaa应助科研通管家采纳,获得30
7秒前
7秒前
orixero应助科研通管家采纳,获得10
7秒前
大个应助科研通管家采纳,获得10
7秒前
SciGPT应助科研通管家采纳,获得10
7秒前
8秒前
所所应助过氧化氢采纳,获得10
10秒前
青山发布了新的文献求助50
11秒前
11秒前
大白发布了新的文献求助10
11秒前
11秒前
热情的达完成签到,获得积分10
11秒前
酷波er应助十九岁的时差采纳,获得10
11秒前
gj发布了新的文献求助10
12秒前
Hairee发布了新的文献求助10
12秒前
momo发布了新的文献求助10
16秒前
称心尔曼完成签到,获得积分10
17秒前
19秒前
21秒前
谷蓝完成签到,获得积分10
21秒前
23秒前
希望天下0贩的0应助Hairee采纳,获得10
24秒前
Rondab应助ali采纳,获得30
25秒前
懒羊羊完成签到,获得积分10
25秒前
好吃完成签到,获得积分20
25秒前
好吃发布了新的文献求助10
28秒前
28秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989297
求助须知:如何正确求助?哪些是违规求助? 3531418
关于积分的说明 11253893
捐赠科研通 3270097
什么是DOI,文献DOI怎么找? 1804884
邀请新用户注册赠送积分活动 882087
科研通“疑难数据库(出版商)”最低求助积分说明 809158